Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | |
---|---|
Operating cash flow (Indirect Method) | |
Cash from operating activities | 398.64M |
Net profit before non-cash adjustment | --404.27M |
Total adjustment of non-cash items | --471K |
-Depreciation and amortization | --2.1M |
-Disposal profit | ---186K |
-Other non-cash items | ---1.44M |
Changes in working capital | ---6.1M |
-Change in receivables | ---4.44M |
-Change in inventory | ---4.76M |
-Change in prepaid assets | ---8.54M |
-Change in payables | --17.71M |
-Change in accrued expense | --5.51M |
-Provision for loans, leases and other losses | --7.06M |
-Changes in other current assets | ---18.64M |
Dividends paid (cash flow from operating activities) | |
Dividends received (cash flow from operating activities) | |
Interest paid (cash flow from operating activities) | -581K |
Interest received (cash flow from operating activities) | 6K |
Tax refund paid | -132.62M |
Other operating cash inflow (outflow) | -1K |
Operating cash flow | --265.45M |
Investing cash flow | |
Net PPE purchase and sale | ---2.08M |
Net investment product transactions | ---14.81M |
Net changes in other investments | ---1K |
Investing cash flow | ---16.88M |
Financing cash flow | |
Net issuance payments of debt | ---87.84M |
Financing cash flow | ---87.84M |
Net cash flow | |
Beginning cash position | --577.58M |
Current changes in cash | --160.72M |
End cash Position | --738.3M |
Free cash flow | --263.37M |
Currency Unit | JPY |
Accounting Standards | NonUS-GAAP |